Deal Watch: Allergan Buys Kythera Anticipating Kybella Will Bolster Its Aesthetic Portfolio
Executive Summary
Johnson & Johnson Innovation announces a spate of 17 deals, bringing its two-year total to more than 200 agreements. Celgene pays $82.5 million up front to partner with Kythera on a ROR gamma T program for cancer immunotherapy.
You may also be interested in...
J&J Sprouts New Innovation Centers In Industry Hot Spots
In an effort to expand outreach to and interaction with innovation-rich communities, J&J is creating four new regional innovation centers to act as scouts, deal-makers and alliance managers in Shanghai, Boston, California and London.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.